Fundraising FoxRezera
5 known investors
Find your way into Rezera
Sign up to see every warm intro you have to Rezera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rezera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation. The company operates in the biotechnology and drug development sector.
Founders & leadership
GM
Geoff McDonoughExecutive Team / BoardGeoff McDonough is an executive with experience in biotech leadership, fundraising, commercial strategy, clinical development, and reimbursement across multiple therapeutic areas. He also serves as an independent director and has been involved in rare disease advocacy.
CG
Chris GuiffreExecutive TeamChris Guiffre held CFO and COO roles at Cubist and Pear Therapeutics, leading public offerings at Cerulean and Pear and raising over $850 million in debt and equity financings across biotech companies.
AP
Alan P. WattExecutive TeamAlan P. Watt has held leadership roles in drug discovery and development, with experience spanning target validation through clinical development. His expertise includes lead optimization, drug metabolism and pharmacokinetics, preclinical development, and therapeutic programs in immunoinflammation and neuroscience.
JG
Jyothis GeorgeChief Medical OfficerJyothis George previously held clinical and regulatory leadership roles across pharmaceutical companies spanning target validation through regulatory approval, with over a decade managing clinical development programs in diabetes, heart failure, and chronic kidney disease. He trained as a clinical endocrinologist and Chief Investigator at the University of Oxford before moving into industry roles including medical affairs, business development, and cross-functional leadership at Amgen and other major pharmaceutical firms.
Investors · 5
5AM Ventureslisted by 5AM VenturesSan Francisco · $100K – $4M
How we know: 5AM Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
Epidarex Capitallisted by Epidarex CapitalBethesda · $2.5M – $6.3M
How we know: Epidarex Capital's portfolio page · Not right? Tell us
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us
Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M
How we know: Sofinnova Partners's portfolio page · a partner's Signal profile · Not right? Tell us
Related companies · 7
RayTheraA biopharmaceutical company developing therapies for neurology, immunology, and rare diseases. The page describes work focused on treating hard-to-treat conditions.
SonoTheraSonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Neurona TherapeuticsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.
AltaThera PharmaceuticalsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
ActitheraActithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
KayoTheraKayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
Companies working in the same space as Rezera.
Frequently asked questions
- What does Rezera do?
- NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation. The company operates in the biotechnology and drug development sector.
- Who are Rezera's investors?
- Rezera's investors include 5AM Ventures, Epidarex Capital, F-Prime Capital, Sanofi Ventures, Sofinnova Partners.